Developer docs
API playgroundTry for free, no card

Search company profiles

Polymun Scientific

Full company profile

uuid000t6tb

Namestring
Polymun Scientific
Legal namestring
Polymun Scientific Immunbiologische Forschung GmbH
Websiteurl
polymun.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Polymun Scientific Immunbiologische Forschung GmbH is an Austrian, family-owned contract development and manufacturing organization (CDMO) founded in 1992 by Prof. Hermann Katinger in Klosterneuburg, Austria. The company operates two integrated technology platforms: (1) biopharmaceutical CDMO services built on mammalian cell culture (CHO-based expression), BAC technology for high-yield cell line development, fed-batch and perfusion fermentation (up to 2x 2,500 L), downstream processing, aseptic filling and freeze-drying; and (2) liposomal and lipid nanoparticle (LNP) formulation services using a proprietary single-step crossflow injection process protected by patents in the US, EU, Australia and Canada. Approximately 100 highly qualified staff (50% holding academic titles) execute work under Austrian Pharmaceutical Law §63 GMP license, with EMA (most recent inspection December 2025) and FDA (most recent July 2023) regulatory oversight.

Polymun generates revenue from three streams: contract development and manufacturing services for pharmaceutical and biotech clients (the dominant stream, covering innovator and biosimilar biologics, vaccines, and LNP-formulated drugs), licensing of proprietary technology platforms and pipeline products (e.g., rhFSH biosimilar Bemfola licensed to Gedeon Richter, recombinant porcine trypsin licensed to Laurus Bio, Lipoxysan licensed to SCARLETRED), and direct sales of HIV antibodies and antigens as research reagents. Customer relationships include BioNTech (Comirnaty COVID-19 vaccine and additional mRNA-LNP programs), CureVac, Arcturus Therapeutics, Takeda (Ceprotin), Imperial College London, IAVI, AC Immune, MiNA Therapeutics, Omega Therapeutics, and approximately 20 other named enterprise and academic clients spanning pre-clinical through commercial supply. The company also maintains an internal R&D pipeline (Lipoxysan, cEPO-Fc, HIV broadly neutralizing antibodies, recombinant porcine trypsin) and is fully owned by the Katinger family with no external institutional investment.

The business model combines fee-for-service CDMO contracts, milestone/license payments on proprietary technology, and high-margin research reagent sales. Go-to-market is enterprise B2B direct sales supported by scientific publication, conference participation, and EU research network engagement. The company has no consumer-facing distribution, no digital products, and no AI/ML capability disclosed in available data.

Short descriptiontext

Polymun Scientific is a private Austrian CDMO founded in 1992 providing contract development and GMP manufacturing of biopharmaceuticals (CHO cell culture) and proprietary liposomal/LNP formulations for pharmaceutical, biotech, and academic clients worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKlosterneuburg, Austria
HQ citystring
Klosterneuburg
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract biopharmaceutical manufacturing, liposomal formulation development, recombinant protein production, lipid nanoparticle drug delivery, GMP clinical manufacturing
Industry2 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Development and Manufacturing (CDMO Services)
TypeProfessional Services
Description

Polymun generates revenue by providing contract development and manufacturing services to pharmaceutical and biotech companies. Services cover the full value chain from gene to clinical-grade material: cell line development, process development, GMP production, filling, release and stability testing, and regulatory support for both innovator and biosimilar biopharmaceutical products, as well as liposomal/LNP formulations.

polymun.com
2Licensing of Proprietary Technologies and Pipeline Products
TypeLicensing Royalties
Description

Polymun licenses its proprietary liposome/LNP technology and product pipeline (e.g., cEPO-Fc, Lipoxysan, HIV antibodies) to partners. Revenue generated from license agreements (e.g., exclusive worldwide license for rhFSH (Bemfola) to Gedeon Richter, license agreement for Lipoxysan with SCARLETRED Holding, recombinant porcine trypsin licensed to Laurus Bio). R&D projects open for co-development and licensing.

polymun.com
3Research Reagents Sales
TypeOne Time License
Description

Direct sales of HIV antibodies (e.g., 2F5, 2G12, 4E10, b12, PG9, PG16) and HIV antigens (UG37gp140, CN54gp140) to research institutions. Products manufactured in CHO cells or E. coli; priced per mg (e.g., €700/mg for antibodies, €500/250μg for antigens). Payment via bank transfer; net 30 days.

polymun.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details5 tiers
1HIV Antibodies - 1 mg unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€700 per mg for individual antibody (e.g., 2F5, 2G12, 4E10, b12, PG9, PG16, etc.). Prices exclusive of VAT. Shipping charges must be covered by buyer. Payment terms: net 30 days via bank transfer.

polymun.com
2HIV Antibodies - 5 mg unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€3,000 per 5 mg for individual antibody. Prices exclusive of VAT. Volume discounts may be available.

polymun.com
3HIV Antigens - 250 μg unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€500 per 250 μg per individual antigen (UG37gp140, CN54gp140, UG21gp140, BR29gp140). Prices exclusive of VAT. CN54gp140 also available in GMP quality for clinical study supply.

polymun.com
4HIV Antigens - 1 mg unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€2,000 per 1 mg per individual antigen. Prices exclusive of VAT.

polymun.com
5HIV Antigens - 5 mg unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€8,000 per 5 mg per individual antigen. Special price arrangements possible for high volume orders.

polymun.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Lipoxysan
Description

Liposomal formulation of recombinant human Cu/Zn superoxide dismutase (SOD) for topical application and inhalation, developed for treatment of Induratio Penis Plastica (Peyronie's disease), inflammatory skin disorders, and chronic skin ulcers.

polymun.com
Core offering1 text field

Polymun Scientific provides contract development and GMP manufacturing services for biopharmaceuticals, including recombinant proteins, antibodies, and liposomal/lipid nanoparticle (LNP) drug products, from cell line development through clinical and commercial supply. The company also produces and sells HIV antigens and antibodies as research reagents.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 250 liters of liposome preparation produced in 1.5 hours using crossflow injection technology
+8 more records
Product overview1 text field

Polymun Scientific is a contract development and manufacturing organization (CDMO) offering two core technology platforms: biopharmaceutical contract manufacturing using mammalian cell culture (CHO cells) for recombinant proteins, antibodies, hormones, and enzymes; and liposomal/LNP formulation services using proprietary crossflow injection technology. The company also provides research reagents including HIV antibodies/antigens and recombinant enzymes, along with internal R&D programs for liposomal superoxide dismutase (Lipoxysan™), carbamylated erythropoietin-Fc fusion protein, and HIV broadly neutralizing antibodies. GMP production services span fermentation, downstream processing, filling, and regulatory support for clinical and commercial supply.

Product and service5 records
1Biopharmaceutical Contract Development and Manufacturing
CategoryContract Development and Manufacturing (CDMO)
Description

End-to-end contract development and GMP manufacturing services for recombinant proteins and monoclonal antibodies, covering cell line development, upstream and downstream processing, formulation, and fill-finish for clinical and commercial supply. Targeted at pharmaceutical and biotechnology companies seeking outsourced manufacturing capacity.

2Liposomal/LNP Formulation Development and Manufacturing
CategoryContract Development and Manufacturing (CDMO)
Description

Contract development and GMP manufacturing of liposomal and lipid nanoparticle (LNP) drug products, leveraging Polymun's proprietary crossflow injection liposome technology. Intended for pharma and biotech developers of vaccines, mRNA therapeutics, and other lipid-based drug products.

3Clinical and Regulatory Support Services
CategoryRegulatory and Quality Services
Description

Regulatory affairs, Qualified Person (QP), clinical, and medical affairs support accompanying contract manufacturing projects, helping clients navigate GMP compliance, product release, and clinical/commercial registration. Designed for pharma and biotech sponsors lacking internal regulatory infrastructure.

4HIV Antibodies (Research Reagents)
CategoryResearch Reagents
Description

Catalog of HIV-specific antibodies supplied as research reagents for academic, government, and industrial HIV research laboratories. Sold directly per unit through the company's catalog.

5HIV Antigens (Research Reagents)
CategoryResearch Reagents
Description

Catalog of HIV antigens supplied as research reagents for basic and translational HIV research, assay development, and vaccine studies. Sold directly per unit through the company's catalog.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership31 partners
1BioNTech SE (Germany)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Polymun is a key manufacturing partner for BioNTech's LNP-mRNA vaccine and therapeutic programs. Polymun established manufacturing processes and performed GMP production for multiple BioNTech programs including the COVID-19 vaccine Comirnaty (BioNTech/Pfizer) — the first licensed COVID-19 vaccine. Additional programs include mRNA for malaria (Plasmodium falciparum, Phase 1/2), tuberculosis (Phase 1), HSV-2 (Phase 1), therapeutic antibody (Phase 2), and cell therapy applications.

polymun.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

License and development agreement for Lipoxysan (liposomal superoxide dismutase) for development and marketing across multiple indications including Peyronie's disease, inflammatory skin disorders, chronic skin ulcers, and cosmetic anti-aging products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun implemented manufacturing processes and performed GMP production for Arcturus' LNP-mRNA coronavirus vaccine. The vaccine (Kostaive) is approved in Japan, completed Phase 3 in Vietnam, and Phase 1/2 in Singapore.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun established manufacturing processes and performed GMP production for CureVac's LNP-mRNA coronavirus vaccine. CureVac's vaccine underwent Phase 3 trials in Europe and Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple collaborations: LNP formulation of self-amplifying RNA as coronavirus vaccine (Phase 1, UK & Uganda); EU H2020 project EAVI2020 coordinated by Imperial College London involving eight trimeric HIV envelope proteins (Phase 0 in UK, Phase 1 in Netherlands and Spain).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Gedeon Richter acquired Finox AG (Polymun's original license partner for rhFSH/biosimilar Bemfola) and became Polymun's new exclusive license partner worldwide. Polymun remains the exclusive manufacturer of rhFSH (Bemfola) as drug substance. Bemfola is approved in multiple countries including EU, Australia, New Zealand, Korea, and Israel.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun is a partner with IAVI on saponin/MPLA nanoparticles (SMNP) developed at MIT Koch Institute as adjuvant for HIV candidate vaccines. Polymun performed development of process and analytical methods and GMP production for Phase 1 clinical trial in USA. Polymun also partners with IAVI through EU H2020 project EHVA.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun provides GMP production of bulk material and prepares affinity chromatography gel for Takeda's HPC-4 murine monoclonal antibody used for affinity purification of protein C (Ceprotin), which is in-market globally.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed formulation and process development and GMP production of liposomal curcumin for cancer treatment. Phase 2 ongoing in USA.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

License agreement for recombinant porcine trypsin technology. Laurus Bio (formerly Richcore Lifesciences Pvt Ltd, Bangalore, India) manufactures recombinant porcine trypsin in large-scale kilogram quantities for use in GMP processes.

11Apeiron Biologics AG (Austria)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun provides process development, GMP drug substance and drug product manufacturing for recombinant human soluble ACE2 (for COVID-19 therapy and renin angiotensin system disorders). Also collaborated on Ch14.18 (Dinutuximab beta) for neuroblastoma with CCRI Vienna. Phase 2 ongoing in USA, Canada & Europe.

polymun.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun established manufacturing process and analytical methods and performs GMP production for Omega's Omega Epigenomic Controller (OEC) mRNA medicine OTX-2002 delivered by LNPs for cancer treatment. Phase 1/2 ongoing.

13Ethris GmbH (Germany)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun developed manufacturing process and analytical methods and performs GMP production of drug product for Ethris' LNP formulation of mRNA coding for type III interferon (ETH47). Phase 1 ongoing in USA.

polymun.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun develops manufacturing process and analytical methods and performs GMP production and filling for Ukko's LNP formulation of mRNA coding for peanut allergens. Preclinical stage.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun established manufacturing process and analytical methods and performs GMP production for InteRNA's LNP formulation of miRNA INT-1B3 for treatment of advanced solid tumors. Phase 1 ongoing in Europe.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed process development and GMP production for MiNA's liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatment. Phase 2 ongoing in Singapore, Taiwan, USA, UK.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed process development and GMP production for AC Immune's ACI-24 liposomal Alzheimer's disease vaccine with MPLA adjuvant. Phase 2 ongoing in Europe & USA.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun established manufacturing process and analytical methods for empty liposomes and produced non-GMP and GMP batches as bulk intermediate for Avvio's microbubbles filled with gas for treatment of ureteral stones using low-intensity ultrasound. Clinical study ongoing in USA.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed process development and GMP production for Dicerna's liposomal formulation of siRNA. Work spans preclinical and clinical stages.

20Wittycell SA (now Abivax, France)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed formulation, process development and GMP production for Wittycell's liposomal adjuvant WTCc. Phase 1/2a ongoing in South Africa.

polymun.com
21ProNAi Inc. (USA)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed process development and GMP production for ProNAi's liposomal DNAi PNT100 with Smarticle technology for cancer treatment. Phase 2 completed in USA.

polymun.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed process development and GMP production for Mirna's liposomal miRNA MRX34 with Smarticle technology for cancer treatment. Phase 1 completed in USA.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed formulation and process development and GMP production for Sanochemia's liposomal formulation of galantamine for treatment of neuropathic pain. Phase 1/2a completed in Bulgaria.

24EuroNeut-41 / Sanofi-Pasteur (France)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

EU FP7 project coordinated by Sanofi-Pasteur. Polymun performed formulation and process development and GMP production for liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccine. Phase 1 completed in UK.

polymun.com
25SurgiMab SAS (France)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polymun optimized manufacturing process for antibody production and conjugation, and produced GMP bulk drug substance and drug product for SurgiMab's SGM-101 (antibody conjugated to near-infrared fluorochrome for cancer detection during surgery). Phase 3 ongoing in Europe & US.

polymun.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed cell line and process development and GMP production for Netris' humanized anti-Netrin-1 monoclonal antibody for cancer treatment. Phase 1b/2 ongoing in Europe.

27GeNeuro SA (Switzerland/France)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed cell line and process development and GMP production for GeNeuro's GNbAC1 humanized monoclonal IgG4 for treatment of multiple sclerosis. Phase 2 ongoing in Europe & Australia.

polymun.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun performed cell line and process development and GMP production for Uvax's HIV envelope protein as self-assembling nanoparticles (HIV vaccine candidate). Phase 1 ongoing in Australia.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Polymun developed expression system and manufacturing process and supplies GMP bulk formulated drug product for Arwan's erythropoietin biosimilar (Alpeen). In-market in Lebanon, Jordan, Kenya, Libya.

30NATPRIME (European Training Network)
Strategic tierMinorTypeOthers
Description

Polymun is a partner in the European Training Network NATPRONE, enhancing visibility in academic research community and facilitating knowledge exchange.

polymun.com
31BIOMOLMACS (European Training Network)
Strategic tierMinorTypeOthers
Description

Polymun is a partner in the European Training Network BIOMOLMACS, supporting research collaboration and training.

polymun.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CordenPharma is a European CDMO with strong capabilities in lipid nanoparticle (LNP) excipients and liposomal formulation services, directly competing with Polymun's liposome/LNP CDMO business for nucleic acid, mRNA, and complex injectable programs serving pharma/biotech clients.

TypeDirect peer
Description

Evonik offers LNP formulation services and specialty lipid excipients (including for mRNA COVID vaccines), directly competing with Polymun's proprietary crossflow injection LNP technology for nucleic acid drug product manufacturing.

TypeBroad incumbent
Description

Catalent is a large global CDMO with broad biologics manufacturing and LNP formulation capabilities (including partnership in Moderna COVID vaccine production). It serves similar pharma/biotech customers for gene therapy, biologics, and LNP work and represents Polymun's largest scaled competitor in overlapping service lines.

TypeBroad incumbent
Description

Lonza is one of the world's largest biologics CDMOs offering mammalian cell culture, antibody manufacturing, and LNP services. It competes with Polymun for mammalian-based recombinant protein and antibody contracts at clinical and commercial scale.

TypeBroad incumbent
Description

WuXi Biologics is a leading global biologics CDMO offering mammalian cell-based antibody and recombinant protein manufacturing from cell line development through commercial supply, directly competing with Polymun's biopharmaceutical CDMO offering for innovator and biosimilar sponsors.

TypeBroad incumbent
Description

Samsung Biologics is a large-scale biologics CDMO offering mammalian cell culture manufacturing with multi-site capacity for antibodies and recombinant proteins, comparable to Polymun's biopharma services but at materially larger commercial scale.

TypeDirect peer
Description

Rentschler is a European-based, family-influenced CDMO specializing in mammalian cell-based recombinant protein and antibody manufacturing. It is closely comparable to Polymun in service scope, European heritage, and focus on clinical-to-commercial supply.

8Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Boehringer Ingelheim's BioXcellence is a global CDMO offering mammalian cell culture-based biologics manufacturing (antibodies, recombinant proteins) from process development to commercial supply, competing with Polymun for mammalian biopharma contracts.

TypeBroad incumbent
Description

AGC Biologics is a global CDMO providing mammalian cell culture manufacturing of antibodies, recombinant proteins, and viral vectors with multi-site capacity, competing with Polymun's biopharma CDMO offering for pharma/biotech sponsors.

TypeBroad incumbent
Description

Baxter BioPharma Solutions is a global CDMO providing parenteral manufacturing services including complex injectables, biologics fill-finish, and formulation, comparable in certain respects to Polymun's formulation, aseptic filling, and contract manufacturing capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers23 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polymun Scientific

Biopharmaceutical Contract Manufacturing (CDMO)polymun.com

Polymun Scientific is a private Austrian CDMO founded in 1992 providing contract development and GMP manufacturing of biopharmaceuticals (CHO cell culture) and proprietary liposomal/LNP formulations for pharmaceutical, biotech, and academic clients worldwide.

What Polymun Scientific does

Polymun Scientific Immunbiologische Forschung GmbH is an Austrian, family-owned contract development and manufacturing organization (CDMO) founded in 1992 by Prof. Hermann Katinger in Klosterneuburg, Austria. The company operates two integrated technology platforms: (1) biopharmaceutical CDMO services built on mammalian cell culture (CHO-based expression), BAC technology for high-yield cell line development, fed-batch and perfusion fermentation (up to 2x 2,500 L), downstream processing, aseptic filling and freeze-drying; and (2) liposomal and lipid nanoparticle (LNP) formulation services using a proprietary single-step crossflow injection process protected by patents in the US, EU, Australia and Canada. Approximately 100 highly qualified staff (50% holding academic titles) execute work under Austrian Pharmaceutical Law §63 GMP license, with EMA (most recent inspection December 2025) and FDA (most recent July 2023) regulatory oversight.

Polymun generates revenue from three streams: contract development and manufacturing services for pharmaceutical and biotech clients (the dominant stream, covering innovator and biosimilar biologics, vaccines, and LNP-formulated drugs), licensing of proprietary technology platforms and pipeline products (e.g., rhFSH biosimilar Bemfola licensed to Gedeon Richter, recombinant porcine trypsin licensed to Laurus Bio, Lipoxysan licensed to SCARLETRED), and direct sales of HIV antibodies and antigens as research reagents. Customer relationships include BioNTech (Comirnaty COVID-19 vaccine and additional mRNA-LNP programs), CureVac, Arcturus Therapeutics, Takeda (Ceprotin), Imperial College London, IAVI, AC Immune, MiNA Therapeutics, Omega Therapeutics, and approximately 20 other named enterprise and academic clients spanning pre-clinical through commercial supply. The company also maintains an internal R&D pipeline (Lipoxysan, cEPO-Fc, HIV broadly neutralizing antibodies, recombinant porcine trypsin) and is fully owned by the Katinger family with no external institutional investment.

The business model combines fee-for-service CDMO contracts, milestone/license payments on proprietary technology, and high-margin research reagent sales. Go-to-market is enterprise B2B direct sales supported by scientific publication, conference participation, and EU research network engagement. The company has no consumer-facing distribution, no digital products, and no AI/ML capability disclosed in available data.

Polymun Scientific firmographics

Firmographics
Name
Polymun Scientific
Legal name
Polymun Scientific Immunbiologische Forschung GmbH
Website
https://polymun.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
11–50 employees
Short description
Polymun Scientific is a private Austrian CDMO founded in 1992 providing contract development and GMP manufacturing of biopharmaceuticals (CHO cell culture) and proprietary liposomal/LNP formulations for pharmaceutical, biotech, and academic clients worldwide.
Ownership category
akta.pro rank

Polymun Scientific industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract biopharmaceutical manufacturing
  • Liposomal formulation development
  • Recombinant protein production
  • Lipid nanoparticle drug delivery
  • GMP clinical manufacturing

Where Polymun Scientific is headquartered

Location

Headquarters

HQ city
Klosterneuburg
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

Polymun Scientific business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO Services): Polymun generates revenue by providing contract development and manufacturing services to pharmaceutical and biotech companies. Services cover the full value chain from gene to clinical-grade material: cell line development, process development, GMP production, filling, release and stability testing, and regulatory support for both innovator and biosimilar biopharmaceutical products, as well as liposomal/LNP formulations.
  2. Licensing of Proprietary Technologies and Pipeline Products: Polymun licenses its proprietary liposome/LNP technology and product pipeline (e.g., cEPO-Fc, Lipoxysan, HIV antibodies) to partners. Revenue generated from license agreements (e.g., exclusive worldwide license for rhFSH (Bemfola) to Gedeon Richter, license agreement for Lipoxysan with SCARLETRED Holding, recombinant porcine trypsin licensed to Laurus Bio). R&D projects open for co-development and licensing.
  3. Research Reagents Sales: Direct sales of HIV antibodies (e.g., 2F5, 2G12, 4E10, b12, PG9, PG16) and HIV antigens (UG37gp140, CN54gp140) to research institutions. Products manufactured in CHO cells or E. coli; priced per mg (e.g., €700/mg for antibodies, €500/250μg for antigens). Payment via bank transfer; net 30 days.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHIV Antibodies - 1 mg unit
Unit PricingPay-as-you-goHIV Antibodies - 5 mg unit
Unit PricingPay-as-you-goHIV Antigens - 250 μg unit
Unit PricingPay-as-you-goHIV Antigens - 1 mg unit
Unit PricingPay-as-you-goHIV Antigens - 5 mg unit

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Polymun Scientific product offering

Product offering

Core offering

Polymun Scientific provides contract development and GMP manufacturing services for biopharmaceuticals, including recombinant proteins, antibodies, and liposomal/lipid nanoparticle (LNP) drug products, from cell line development through clinical and commercial supply. The company also produces and sells HIV antigens and antibodies as research reagents.

Product overview

Polymun Scientific is a contract development and manufacturing organization (CDMO) offering two core technology platforms: biopharmaceutical contract manufacturing using mammalian cell culture (CHO cells) for recombinant proteins, antibodies, hormones, and enzymes; and liposomal/LNP formulation services using proprietary crossflow injection technology. The company also provides research reagents including HIV antibodies/antigens and recombinant enzymes, along with internal R&D programs for liposomal superoxide dismutase (Lipoxysan™), carbamylated erythropoietin-Fc fusion protein, and HIV broadly neutralizing antibodies. GMP production services span fermentation, downstream processing, filling, and regulatory support for clinical and commercial supply.

Differentiator

Problem solved

Functional benefit

Brands

  • Lipoxysan: Liposomal formulation of recombinant human Cu/Zn superoxide dismutase (SOD) for topical application and inhalation, developed for treatment of Induratio Penis Plastica (Peyronie's disease), inflammatory skin disorders, and chronic skin ulcers.

Products and services

  • Biopharmaceutical Contract Development and Manufacturing End-to-end contract development and GMP manufacturing services for recombinant proteins and monoclonal antibodies, covering cell line development, upstream and downstream processing, formulation, and fill-finish for clinical and commercial supply. Targeted at pharmaceutical and biotechnology companies seeking outsourced manufacturing capacity.
  • Liposomal/LNP Formulation Development and Manufacturing Contract development and GMP manufacturing of liposomal and lipid nanoparticle (LNP) drug products, leveraging Polymun's proprietary crossflow injection liposome technology. Intended for pharma and biotech developers of vaccines, mRNA therapeutics, and other lipid-based drug products.
  • Clinical and Regulatory Support Services Regulatory affairs, Qualified Person (QP), clinical, and medical affairs support accompanying contract manufacturing projects, helping clients navigate GMP compliance, product release, and clinical/commercial registration. Designed for pharma and biotech sponsors lacking internal regulatory infrastructure.
  • HIV Antibodies (Research Reagents) Catalog of HIV-specific antibodies supplied as research reagents for academic, government, and industrial HIV research laboratories. Sold directly per unit through the company's catalog.
  • HIV Antigens (Research Reagents) Catalog of HIV antigens supplied as research reagents for basic and translational HIV research, assay development, and vaccine studies. Sold directly per unit through the company's catalog.

Quantifiable outcome

  • 250 liters of liposome preparation produced in 1.5 hours using crossflow injection technology
  • +8 more outcomes

Companies that use Polymun Scientific

Customer profile

Named customers23 records

Segments3 records

Ideal customer profiles2 records

Polymun Scientific technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Polymun Scientific partnerships and signals

Strategic signal

Partnerships

31 partnerships are on record, tiered core and minor.

  • BioNTech SE (Germany)coreStrategic or Co-development Partner · 1 January 2020Polymun is a key manufacturing partner for BioNTech's LNP-mRNA vaccine and therapeutic programs. Polymun established manufacturing processes and performed GMP production for multiple BioNTech programs including the COVID-19 vaccine Comirnaty (BioNTech/Pfizer) — the first licensed COVID-19 vaccine. Additional programs include mRNA for malaria (Plasmodium falciparum, Phase 1/2), tuberculosis (Phase 1), HSV-2 (Phase 1), therapeutic antibody (Phase 2), and cell therapy applications.
  • SCARLETRED Holding GmbH (Austria)minorStrategic or Co-development Partner · 1 January 2015License and development agreement for Lipoxysan (liposomal superoxide dismutase) for development and marketing across multiple indications including Peyronie's disease, inflammatory skin disorders, chronic skin ulcers, and cosmetic anti-aging products.
  • Arcturus Therapeutics Inc. (USA)coreStrategic or Co-development PartnerPolymun implemented manufacturing processes and performed GMP production for Arcturus' LNP-mRNA coronavirus vaccine. The vaccine (Kostaive) is approved in Japan, completed Phase 3 in Vietnam, and Phase 1/2 in Singapore.
  • CureVac (Germany)coreStrategic or Co-development PartnerPolymun established manufacturing processes and performed GMP production for CureVac's LNP-mRNA coronavirus vaccine. CureVac's vaccine underwent Phase 3 trials in Europe and Latin America.
  • Imperial College London (UK)coreStrategic or Co-development PartnerMultiple collaborations: LNP formulation of self-amplifying RNA as coronavirus vaccine (Phase 1, UK & Uganda); EU H2020 project EAVI2020 coordinated by Imperial College London involving eight trimeric HIV envelope proteins (Phase 0 in UK, Phase 1 in Netherlands and Spain).
  • Gedeon Richter (Hungary)coreStrategic or Co-development PartnerGedeon Richter acquired Finox AG (Polymun's original license partner for rhFSH/biosimilar Bemfola) and became Polymun's new exclusive license partner worldwide. Polymun remains the exclusive manufacturer of rhFSH (Bemfola) as drug substance. Bemfola is approved in multiple countries including EU, Australia, New Zealand, Korea, and Israel.
  • International AIDS Vaccine Initiative (IAVI, USA)coreStrategic or Co-development PartnerPolymun is a partner with IAVI on saponin/MPLA nanoparticles (SMNP) developed at MIT Koch Institute as adjuvant for HIV candidate vaccines. Polymun performed development of process and analytical methods and GMP production for Phase 1 clinical trial in USA. Polymun also partners with IAVI through EU H2020 project EHVA.
  • Takeda (formerly Baxter AG, Austria)coreStrategic or Co-development PartnerPolymun provides GMP production of bulk material and prepares affinity chromatography gel for Takeda's HPC-4 murine monoclonal antibody used for affinity purification of protein C (Ceprotin), which is in-market globally.
  • Signpath Pharma (USA)minorStrategic or Co-development PartnerPolymun performed formulation and process development and GMP production of liposomal curcumin for cancer treatment. Phase 2 ongoing in USA.
  • Laurus Bio Pvt Ltd (India)minorStrategic or Co-development PartnerLicense agreement for recombinant porcine trypsin technology. Laurus Bio (formerly Richcore Lifesciences Pvt Ltd, Bangalore, India) manufactures recombinant porcine trypsin in large-scale kilogram quantities for use in GMP processes.
  • Apeiron Biologics AG (Austria)coreStrategic or Co-development PartnerPolymun provides process development, GMP drug substance and drug product manufacturing for recombinant human soluble ACE2 (for COVID-19 therapy and renin angiotensin system disorders). Also collaborated on Ch14.18 (Dinutuximab beta) for neuroblastoma with CCRI Vienna. Phase 2 ongoing in USA, Canada & Europe.
  • Omega Therapeutics Inc. (USA)coreStrategic or Co-development PartnerPolymun established manufacturing process and analytical methods and performs GMP production for Omega's Omega Epigenomic Controller (OEC) mRNA medicine OTX-2002 delivered by LNPs for cancer treatment. Phase 1/2 ongoing.
  • Ethris GmbH (Germany)minorStrategic or Co-development PartnerPolymun developed manufacturing process and analytical methods and performs GMP production of drug product for Ethris' LNP formulation of mRNA coding for type III interferon (ETH47). Phase 1 ongoing in USA.
  • Ukko Inc. (USA)minorStrategic or Co-development PartnerPolymun develops manufacturing process and analytical methods and performs GMP production and filling for Ukko's LNP formulation of mRNA coding for peanut allergens. Preclinical stage.
  • InteRNA Technologies B.V. (Netherlands)minorStrategic or Co-development PartnerPolymun established manufacturing process and analytical methods and performs GMP production for InteRNA's LNP formulation of miRNA INT-1B3 for treatment of advanced solid tumors. Phase 1 ongoing in Europe.
  • MiNA Therapeutics Ltd. (UK)minorStrategic or Co-development PartnerPolymun performed process development and GMP production for MiNA's liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatment. Phase 2 ongoing in Singapore, Taiwan, USA, UK.
  • AC Immune SA (Switzerland)minorStrategic or Co-development PartnerPolymun performed process development and GMP production for AC Immune's ACI-24 liposomal Alzheimer's disease vaccine with MPLA adjuvant. Phase 2 ongoing in Europe & USA.
  • Avvio Medical Inc. (USA)minorStrategic or Co-development PartnerPolymun established manufacturing process and analytical methods for empty liposomes and produced non-GMP and GMP batches as bulk intermediate for Avvio's microbubbles filled with gas for treatment of ureteral stones using low-intensity ultrasound. Clinical study ongoing in USA.
  • Dicerna Pharmaceuticals, Inc. (USA)minorStrategic or Co-development PartnerPolymun performed process development and GMP production for Dicerna's liposomal formulation of siRNA. Work spans preclinical and clinical stages.
  • Wittycell SA (now Abivax, France)minorStrategic or Co-development PartnerPolymun performed formulation, process development and GMP production for Wittycell's liposomal adjuvant WTCc. Phase 1/2a ongoing in South Africa.
  • ProNAi Inc. (USA)minorStrategic or Co-development PartnerPolymun performed process development and GMP production for ProNAi's liposomal DNAi PNT100 with Smarticle technology for cancer treatment. Phase 2 completed in USA.
  • Mirna Therapeutics Inc. (USA)minorStrategic or Co-development PartnerPolymun performed process development and GMP production for Mirna's liposomal miRNA MRX34 with Smarticle technology for cancer treatment. Phase 1 completed in USA.
  • Sanochemia Pharmazeutika AG (Austria)minorStrategic or Co-development PartnerPolymun performed formulation and process development and GMP production for Sanochemia's liposomal formulation of galantamine for treatment of neuropathic pain. Phase 1/2a completed in Bulgaria.
  • EuroNeut-41 / Sanofi-Pasteur (France)minorStrategic or Co-development PartnerEU FP7 project coordinated by Sanofi-Pasteur. Polymun performed formulation and process development and GMP production for liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccine. Phase 1 completed in UK.
  • SurgiMab SAS (France)coreStrategic or Co-development PartnerPolymun optimized manufacturing process for antibody production and conjugation, and produced GMP bulk drug substance and drug product for SurgiMab's SGM-101 (antibody conjugated to near-infrared fluorochrome for cancer detection during surgery). Phase 3 ongoing in Europe & US.
  • Netris Pharma (France)minorStrategic or Co-development PartnerPolymun performed cell line and process development and GMP production for Netris' humanized anti-Netrin-1 monoclonal antibody for cancer treatment. Phase 1b/2 ongoing in Europe.
  • GeNeuro SA (Switzerland/France)minorStrategic or Co-development PartnerPolymun performed cell line and process development and GMP production for GeNeuro's GNbAC1 humanized monoclonal IgG4 for treatment of multiple sclerosis. Phase 2 ongoing in Europe & Australia.
  • Uvax Bio LLC (USA)minorStrategic or Co-development PartnerPolymun performed cell line and process development and GMP production for Uvax's HIV envelope protein as self-assembling nanoparticles (HIV vaccine candidate). Phase 1 ongoing in Australia.
  • Arwan Pharmaceutical Industries (Lebanon)minorStrategic or Co-development PartnerPolymun developed expression system and manufacturing process and supplies GMP bulk formulated drug product for Arwan's erythropoietin biosimilar (Alpeen). In-market in Lebanon, Jordan, Kenya, Libya.
  • NATPRIME (European Training Network)minorOthersPolymun is a partner in the European Training Network NATPRONE, enhancing visibility in academic research community and facilitating knowledge exchange.
  • BIOMOLMACS (European Training Network)minorOthersPolymun is a partner in the European Training Network BIOMOLMACS, supporting research collaboration and training.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Polymun Scientific competitors and assessment

Company assessment

Direct peers

  • CordenPharma: CordenPharma is a European CDMO with strong capabilities in lipid nanoparticle (LNP) excipients and liposomal formulation services, directly competing with Polymun's liposome/LNP CDMO business for nucleic acid, mRNA, and complex injectable programs serving pharma/biotech clients.
  • Evonik Health Care: Evonik offers LNP formulation services and specialty lipid excipients (including for mRNA COVID vaccines), directly competing with Polymun's proprietary crossflow injection LNP technology for nucleic acid drug product manufacturing.
  • Rentschler Biopharma: Rentschler is a European-based, family-influenced CDMO specializing in mammalian cell-based recombinant protein and antibody manufacturing. It is closely comparable to Polymun in service scope, European heritage, and focus on clinical-to-commercial supply.

Broad incumbents

  • Catalent: Catalent is a large global CDMO with broad biologics manufacturing and LNP formulation capabilities (including partnership in Moderna COVID vaccine production). It serves similar pharma/biotech customers for gene therapy, biologics, and LNP work and represents Polymun's largest scaled competitor in overlapping service lines.
  • Lonza: Lonza is one of the world's largest biologics CDMOs offering mammalian cell culture, antibody manufacturing, and LNP services. It competes with Polymun for mammalian-based recombinant protein and antibody contracts at clinical and commercial scale.
  • WuXi Biologics: WuXi Biologics is a leading global biologics CDMO offering mammalian cell-based antibody and recombinant protein manufacturing from cell line development through commercial supply, directly competing with Polymun's biopharmaceutical CDMO offering for innovator and biosimilar sponsors.
  • Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO offering mammalian cell culture manufacturing with multi-site capacity for antibodies and recombinant proteins, comparable to Polymun's biopharma services but at materially larger commercial scale.
  • Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's BioXcellence is a global CDMO offering mammalian cell culture-based biologics manufacturing (antibodies, recombinant proteins) from process development to commercial supply, competing with Polymun for mammalian biopharma contracts.
  • AGC Biologics: AGC Biologics is a global CDMO providing mammalian cell culture manufacturing of antibodies, recombinant proteins, and viral vectors with multi-site capacity, competing with Polymun's biopharma CDMO offering for pharma/biotech sponsors.
  • Baxter BioPharma Solutions: Baxter BioPharma Solutions is a global CDMO providing parenteral manufacturing services including complex injectables, biologics fill-finish, and formulation, comparable in certain respects to Polymun's formulation, aseptic filling, and contract manufacturing capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Polymun Scientific social profiles

Digital presence

Polymun Scientific compliance and trust

Trust signal

Compliance3 records

Polymun Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polymun Scientific leadership team

Management profile

Number of profiles

Profiles13 records

Polymun Scientific funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polymun Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polymun Scientific

What does Polymun Scientific do?

Polymun Scientific provides contract development and GMP manufacturing services for biopharmaceuticals, including recombinant proteins, antibodies, and liposomal/lipid nanoparticle (LNP) drug products, from cell line development through clinical and commercial supply. The company also produces and sells HIV antigens and antibodies as research reagents.

Is Polymun Scientific a public or private company?

Polymun Scientific is a private company. It is classified as family owned and is currently operating.

When was Polymun Scientific founded?

Polymun Scientific was founded in 1992. It employs 11 to 50 people.

Where is Polymun Scientific based?

Polymun Scientific is headquartered in Klosterneuburg, Austria, in the Europe region.

How does Polymun Scientific make money?

Three revenue lines are on record. Contract Development and Manufacturing (CDMO Services) is the primary driver. The others are licensing of Proprietary Technologies and Pipeline Products and research Reagents Sales.

Who are Polymun Scientific's main competitors?

Direct peers on record are CordenPharma, Evonik Health Care and Rentschler Biopharma. Broad incumbents are Catalent, Lonza, WuXi Biologics, Samsung Biologics, Boehringer Ingelheim BioXcellence, AGC Biologics and Baxter BioPharma Solutions.

Does Polymun Scientific have an API?

No public API is recorded for Polymun Scientific.

What industry is Polymun Scientific in?

Polymun Scientific's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales